Abcellera Biologics is trading 4.5% up at $6.82, staging a technical recovery after several sessions of profit-taking followed a massive 40% rally.
- The recent surge was previously driven by upbeat Q1 2026 results and growing optimism surrounding the company's clinical pipeline.
- With no fresh company-specific news reported today, the move reflects buyers stepping back in following the recent pullback amid broader strength in biotech and growth names.